Codexis, Inc. (CDXS)

Market Cap	231.79M +13.7%
Revenue (ttm)	78.09M +56.8%
Net Income	-31.99M
EPS	-0.36
Shares Out	90.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	201,597
Open	2.530
Previous Close	2.490
Day's Range	2.502 - 2.575
52-Week Range	0.958 - 3.870
Beta	2.53
Analysts	Buy
Price Target	6.58 (+158.04%)
Earnings Date	May 7, 2026

About CDXS

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The co...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 22, 2010
• Employees: 146
• Stock Exchange: NASDAQ
• Ticker Symbol: CDXS
• Website: https://www.codexis.com

Financial Performance

In 2025, Codexis's revenue was $70.39 million, an increase of 18.61% compared to the previous year's $59.35 million. Losses were -$43.97 million, -32.63% less than in 2024.

Analyst Summary

According to 7 analysts, the average rating for CDXS stock is "Buy." The 12-month stock price target is $6.58, which is an increase of 158.04% from the latest price.

Price Target

$6.58

(158.04% upside)

Analyst Consensus: Buy